When Valisure tested ranitidine with salt concentrations approximating safe human ingestion levels ... The focus no longer was on whether the drug was dangerous. Now, it centered around claims of ...

In 2018, Valisure found an impurity that could cause cancer in the heartburn medicine known as Zantac and its generics ... With the ribbon cutting, Valisure now opens a new, bigger, more ...

This is the usual safe harbor statement ... Turning to Slide 4. I will now hand the call to Emma. Welcome to everybody joining us today. Please turn to the next slide. I'm pleased to report ...

On Tuesday, U.S. District Judge Brian Cogan in New York dismissed key consumer claims in the multidistrict litigation against ...

Q3 2024 Earnings Call Transcript October 30, 2024 GSK plc beats earnings expectations. Reported EPS is $1.29, expectations were $1.23. Operator: Hello, everyone. Welcome to today’s call and webcast.

Seeking Alpha analyst and Investing Group leader, Manika Premsingh believes the worst is now behind ... look good and safe as well, even with the earnings impact from the Zantac settlement ...

GSK has also reached an agreement to pay $70 million to resolve the Zantac Qui Tam suit previously ... To apply right now for a loan settlement program, please visit the company's website ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.